8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection

Anatomical Principles and Techniques of Sentinel Lymph Node Staging

Regional axillary nodal status remains one of the single most influential prognostic determinants in early-stage invasive breast cancer, informing staging according to the AJCC TNM system and directing systemic adjuvant recommendations (chemotherapy, targeted biologicals, ovarian suppression) and locoregional radiation fields.

The Sentinel Lymph Node (SLN) Concept

The sentinel lymph node is defined as the first lymph node (or group of initial nodes) that directly receives afferent lymphatic drainage from the primary mammary neoplasm. Based on the ordered, sequential nature of lymphatic transit, if the sentinel node is histologically free of metastatic carcinoma, the remaining downstream non-sentinel axillary nodes are pathologically negative in greater than 95% to 98% of cases. Sentinel lymph node biopsy (SLNB) replaced routine completion axillary dissection as the standard of care for clinically node-negative (cN0) disease, eliminating the heavy morbidity of arm lymphedema and shoulder dysfunction in non-metastatic patients.

Dual-Tracer Mapping Methodology

Clinical guidelines strongly endorse the dual-tracer mapping technique, which combines a radiolabeled colloid with a vital blue dye or fluorescent agent to optimize sentinel node identification and minimize the false-negative rate (FNR):

1. Radiocolloid (Technetium-99m Sulfur Colloid):
   • Injected intradermally, subareolarly, or peritumorally either the morning of surgery or the afternoon prior.
   • Filtered sulfur colloid particles (100 to 220 nm) migrate through lymphatic capillaries and become trapped within the reticuloendothelial sinuses of the sentinel nodes.
   • Intraoperatively, the surgeon utilizes a handheld acoustic gamma probe to identify radioactive 'hot' nodes through transcutaneous and direct tissue acoustic counts.
   • The 10% Rule: Any lymph node exhibiting radioactivity counts ≥10% of the most active ('hottest') sentinel node ex vivo is defined as a sentinel node and must be excised.
2. Vital Blue Dyes (Isosulfan Blue or Methylene Blue):
   • Injected into the subareolar or peritumoral dermal plexus intraoperatively, followed by 5 minutes of gentle parenchymal massage to promote lymphatic uptake.
   • Dyes travel rapidly through superficial lymphatic trunks, visually staining afferent channels and sentinel nodes bright blue.
   • Any node that is visually blue or has a blue lymphatic channel entering it is categorized as a sentinel node.
3. Near-Infrared Fluorescence (Indocyanine Green [ICG]):
   • Emerging optical mapping technique using ICG illuminated by near-infrared light cameras, providing real-time transcutaneous visualization of lymphatic channels without radiation exposure.

Clinical Safety Pearls Regarding Mapping Dyes

• Isosulfan Blue (Lymphazurin): Associated with IgE-mediated allergic reactions in roughly 1% to 2% of patients (severe anaphylaxis in well under 1%), presenting as 'blue hives' (generalized urticaria), acute bronchospasm, and profound cardiovascular collapse. Furthermore, intravascular absorption alters blood light absorbance at 660 nm, causing a transient, false drop in pulse oximetry (SpO2) readings to 85-90% despite normal arterial blood gas oxygen tension (PaO2). Nurses must recognize this benign optical artifact to prevent inappropriate hyperventilation or emergency airway interventions.
• Methylene Blue: Extravasation or superficial intradermal injection can induce severe ischemic dermal necrosis and chronic skin ulceration. Methylene blue is a potent monoamine oxidase A (MAO-A) inhibitor; when administered to patients receiving serotonergic psychotropic medications (SSRIs, SNRIs), it carries a rare risk of precipitating life-threatening serotonin syndrome.

Indications and Absolute Contraindications for SLNB

• Standard Indications: Clinically node-negative (cN0 by physical exam and axillary ultrasound) invasive breast carcinomas (T1 to T3); patients with extensive high-grade DCIS undergoing total mastectomy (because breast removal prevents performing an SLNB later if microinvasive or invasive carcinoma is unexpectedly discovered on permanent pathology).
• Absolute Contraindications:
  1. Inflammatory Breast Cancer: Malignant tumor emboli extensively plug dermal lymphatic channels, causing chaotic, unpredictable retrograde lymphatic diversion that yields an unacceptably high false-negative rate (>20-30%).
  2. Clinically Overt, Biopsy-Proven Axillary Nodal Metastasis (cN1-N2): Patients with palpably matted, fixed, or ultrasound-proven biopsy-positive nodes prior to surgery are not candidates for primary SLNB and require formal axillary clearing (unless undergoing neoadjuvant chemotherapy).

Landmark Clinical Trials Transforming Axillary Surgery

Over the past two decades, prospective randomized clinical trials have revolutionized surgical oncology by demonstrating that aggressive axillary clearance can be safely omitted in selected patient populations without sacrificing locoregional control or overall survival.

Axillary Lymph Node Dissection (ALND) Technique and Boundaries

Standard ALND involves the systematic anatomical en bloc clearance of Berg Level I and Level II axillary lymph nodes, typically retrieving a minimum of 10 nodes for comprehensive histopathological staging. The surgical boundaries of ALND include:

• Superior boundary: Axillary vein and its investing adventitia.
• Lateral boundary: Anterior border and tendon of the latissimus dorsi muscle.
• Medial boundary: Medial border of the pectoralis minor muscle and the serratus anterior muscle (chest wall).
• Anterior boundary: Pectoralis major and minor muscles.
• Posterior boundary / floor: Subscapularis and teres major muscles.

The ACOSOG Z0011 Trial: De-Escalation of Axillary Dissection

The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial challenged the century-old dogma that any positive lymph node mandated completion ALND.

• Inclusion Criteria:
  • Clinical stage T1 or T2 invasive breast cancer (tumor ≤5 cm).
  • Clinically node-negative (cN0) axilla by physical examination.
  • Underwent breast-conserving surgery (lumpectomy) with negative margins.
  • Found to have 1 or 2 positive sentinel lymph nodes with micrometastases or macrometastases on final pathology.
  • Planned for whole-breast external beam tangential radiation therapy and systemic adjuvant therapy (endocrine therapy, chemotherapy, or both).
• Randomization: Completion ALND versus SLNB alone (no further axillary surgery).
• Results at 10-Year Follow-up: Regional (nodal) recurrence was 1.5% with SLNB alone versus 0.5% with ALND (not statistically significant), and local recurrence was also similar. Ten-year overall survival was 86.3% in the SLNB group and 83.6% in the ALND group. Incidental radiation from standard tangential whole-breast radiation fields delivers therapeutic doses to Berg Level I axillary nodes, while effective systemic adjuvant therapies eradicate occult microscopic regional disease.
• Strict Practice Boundaries (When ALND is Still Required):
  • Patients undergoing total mastectomy without planned post-mastectomy radiation.
  • Patients with ≥3 positive sentinel lymph nodes.
  • Patients with gross matted lymph nodes or extensive extranodal extension (ENE) perforating the nodal capsule into axillary fat.
  • Patients treated with partial breast irradiation (PBI) or intraoperative radiation (IORT), which do not cover the low axillary basin.

The AMAROS Trial

The European Organisation for Research and Treatment of Cancer (EORTC) AMAROS trial enrolled patients with cT1-T2 breast cancer and positive SLNB, randomizing them to completion ALND versus axillary radiotherapy (ART).

• Findings: Both arms achieved outstanding, equivalent 10-year axillary recurrence rates (<1.5%) and identical overall survival.
• Lymphedema Morbidity: Axillary radiotherapy resulted in a significantly lower incidence of clinical upper-limb lymphedema at 5 years (11% in the axillary radiation arm versus 23% in the ALND arm). Radiotherapy provides equivalent regional control with half the risk of chronic disabling edema.

Axillary Staging Following Neoadjuvant Chemotherapy (NAC)

In patients who present with biopsy-proven node-positive disease (cN1) and receive neoadjuvant chemotherapy (NAC), complete pathological response (pCR) in the axillary nodes occurs in 40% to 70% of cases (especially high in HER2-positive and triple-negative subtypes). To safely avoid completion ALND in patients who convert from cN1 to clinically node-negative (ycN0), clinical trials (ACOSOG Z1071 and SENTINA) established three strict criteria to lower the false-negative rate below the 10% threshold:

1. Dual-tracer mapping: Both radiocolloid and blue dye must be utilized.
2. Retrieval of ≥3 lymph nodes: In ACOSOG Z1071, removing 3 or more sentinel nodes lowered the FNR to about 9%, versus more than 20% when only 2 were retrieved.
3. Targeted Axillary Dissection (TAD): Placing a radiopaque biopsy clip into the biopsy-positive lymph node prior to starting neoadjuvant therapy, and localizing/retrieving that specific clipped node intraoperatively (using radioactive seeds, wire localization, or radar reflectors) along with the sentinel nodes. Retrieval of the clipped node ensures the FNR is suppressed below 2% to 4%.

Complications of Axillary Surgery and Postoperative Neuropathy

Axillary surgery requires delicate dissection around major neurovascular structures. Iatrogenic nerve injury produces characteristic physical and sensory deficits that breast care nurses must recognize and manage.

Neurological Complications and Nerve Injuries

1. Intercostobrachial Nerve (ICBN) Injury:
   • Anatomy: Originates from the lateral cutaneous branch of the second intercostal nerve (T2) and courses directly across the axillary fat pad of Berg Level I.
   • Clinical Presentation: Stretching, thermal cautery injury, or deliberate transection produces anesthesia, hypesthesia, paresthesias, or painful dysesthesias along the axilla and medial/posterior aspect of the upper ipsilateral arm.
   • Prevalence: The most frequent neurological complication of axillary surgery, occurring in 60% to 80% of ALND and 10% to 20% of SLNB cases.
   • Nursing Management: Educate patients regarding cutaneous numbness to prevent accidental contact burns (testing bathwater with opposite hand, caution with curling irons and cooking) and avoid cuts or razor abrasions. Persistent burning neuropathic pain is managed with gabapentin, pregabalin, or duloxetine.
2. Long Thoracic Nerve (Nerve of Bell) Injury:
   • Anatomy: Arises from the anterior rami of C5, C6, and C7 nerve roots and descends vertically along the medial axillary wall, resting directly on the superficial fascia of the serratus anterior muscle.
   • Clinical Presentation: Denervation of the serratus anterior prevents dynamic stabilization of the scapula against the thoracic cage. This produces a pathognomonic 'winged scapula' (scapular winging), wherein the medial border and inferior angle of the scapula project prominently backward away from the chest wall.
   • Functional Deficit: Scapular winging is accentuated when the patient pushes forward against a wall with outstretched hands (wall push-up test). Patients experience weakness with forward shoulder flexion and inability to abduct the arm above 90 degrees, impairing overhead reaching.
   • Management: Physical therapy emphasizing trapezius and rhomboid strengthening; nerve recovery may require 6 to 18 months; permanent deficits require orthotic bracing or muscle transfer.
3. Thoracodorsal Nerve Injury:
   • Anatomy: Originates from the posterior cord of the brachial plexus (C6-C8) and accompanies the thoracodorsal artery and vein down the lateral axillary wall to innervate the latissimus dorsi muscle.
   • Clinical Presentation: Paresis or paralysis of the latissimus dorsi. Patients exhibit weakness in shoulder adduction, extension, and internal rotation. Clinically, patients struggle to pull their arm down and back against resistance, impairing activities such as swimming, rowing, climbing, or pushing up out of an armchair.
4. Medial Pectoral Nerve Injury:
   • Anatomy: Pierces or wraps around the pectoralis minor muscle to innervate both pectoralis minor and the lower sternal head of the pectoralis major.
   • Clinical Presentation: Denervation atrophy of the lateral and inferior portions of the pectoralis major muscle, producing an unsightly infraclavicular hollow and mild adduction weakness.

Vascular, Lymphatic, and Soft-Tissue Complications

• Seroma Formation: Sterile accumulation of serous fluid and disrupted lymph within the axillary dead space, occurring in up to 30% to 50% of ALND cases. Small seromas resorb spontaneously; large, tense, symptomatic seromas causing wound tension or pain are aspirated percutaneously under strict aseptic technique.
• Axillary Web Syndrome (Cording): A condition characterized by the sudden development of taut, visible, palpable subcutaneous cords spanning from the axilla across the antecubital fossa down to the base of the thumb. Pathophysiologically caused by localized thrombosis, phlebitis, and fibrotic shortening of disrupted lymphatic vessels and superficial veins. Typically manifests 1 to 8 weeks postoperatively. Managed effectively with specialized physical therapy, gentle myofascial release, manual lymphatic drainage, and passive stretching.
• Secondary Upper Extremity Lymphedema: Chronic, progressive interstitial protein-rich fluid accumulation and fibro-adipose deposition resulting from severed axillary lymphatic channels. Occurs in 5% to 7% of SLNB patients, escalating to 15% to 25% after ALND, and reaching 30% to 40% when ALND is combined with regional nodal irradiation (RNI).